{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:19:43Z","timestamp":1790306383497,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jaad.2017.04.1142","type":"journal-article","created":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T21:28:24Z","timestamp":1513027704000},"page":"15-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":247,"title":["Alopecia areata"],"prefix":"10.1016","volume":"78","author":[{"given":"Lauren C.","family":"Strazzulla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy Hsi Chun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Lo Sicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nooshin","family":"Brinster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Christiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2017.04.1142_bib1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0190-9622(91)70032-W","article-title":"Prognostic factors in the treatment of alopecia areata with diphenylcyclopropenone","volume":"24","author":"van der Steen","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jaad.2006.05.008","article-title":"Alopecia areata: a long term follow-up study of 191 patients","volume":"55","author":"Tosti","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1529-8019.2011.01417.x","article-title":"Camouflage technique for alopecia areata: what is a patient to do?","volume":"24","author":"Draelos","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2017.04.1142_bib4","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1046\/j.1365-4362.2002.01357.x","article-title":"The pattern and profile\u00a0of alopecia areata in Singapore\u2013a study of 219 Asians","volume":"41","author":"Tan","year":"2002","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib5","first-page":"909","article-title":"Treatment of\u00a0severe alopecia areata with intralesional steroid injections","volume":"8","author":"Chang","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib6","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2015.04.049","article-title":"Benefit of different concentrations of intralesional triamcinolone acetonide in alopecia areata: an intrasubject pilot study","volume":"73","author":"Chu","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib7","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1111\/bjd.15483","article-title":"Image gallery: treatment of refractory alopecia universalis with oral tofacitinib citrate and adjunct intralesional triamcinolone injections","volume":"176","author":"Strazzulla","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib8","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1067\/mjd.2000.103909","article-title":"Alopecia areata update","volume":"42","author":"Madani","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib9","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00055735-200012000-00016","article-title":"Ocular complications of topical, peri-ocular, and systemic corticosteroids","volume":"11","author":"Carnahan","year":"2000","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1067\/mjd.2003.423","article-title":"Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis\/universalis","volume":"49","author":"Tosti","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib11","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/archderm.136.10.1276","article-title":"Randomized double-blind placebo-controlled trial in the treatment of alopecia areata with 0.25% desoximetasone cream","volume":"136","author":"Charuwichitratana","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000252466","article-title":"Assay of 0.2% fluocinolone acetonide cream for alopecia areata and totalis","volume":"141","author":"Pascher","year":"1970","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2017.04.1142_bib13","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/j.1468-3083.2006.01781.x","article-title":"Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial","volume":"20","author":"Tosti","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003495-198800365-00005","article-title":"Side effects of topical corticosteroids and their prevention","volume":"36","author":"Takeda","year":"1988","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2017.04.1142_bib15","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0190-9622(87)70096-6","article-title":"Topical minoxidil (3%) in extensive alopecia areata, including long-term efficacy","volume":"16","author":"Price","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib16","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0190-9622(87)70095-4","article-title":"Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata","volume":"16","author":"Price","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib17","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1001\/archderm.1992.01680210045005","article-title":"Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata","volume":"128","author":"Olsen","year":"1992","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib18","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0190-9622(87)80003-8","article-title":"Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata","volume":"16","author":"Fiedler-Weiss","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1468-3083.2003.00621.x","article-title":"Hypertrichosis in females applying minoxidil topical solution and in normal controls","volume":"17","author":"Dawber","year":"2003","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib20","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jaad.2010.09.724","article-title":"A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women","volume":"65","author":"Blume-Peytavi","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib21","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0190-9622(98)70009-X","article-title":"Pulse methylprednisolone therapy for severe alopecia areata: an open prospective study of 45 patients","volume":"39","author":"Friedli","year":"1998","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF00455378","article-title":"Long-term intramuscular triamcinolon-acetonide therapy in alopecia areata totalis and universalis","volume":"261","author":"Michalowski","year":"1978","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2017.04.1142_bib23","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/archderm.1973.01620180061019","article-title":"Alopecia areata: immunologic studies and treatment with prednisone","volume":"107","author":"Kern","year":"1973","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annder.2010.06.031","article-title":"Long-term follow-up of the efficacy of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia areata totalis or universalis [in French]","volume":"137","author":"Chartaux","year":"2009","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2133.2011.10383.x","article-title":"Efficacy and tolerability\u00a0of methotrexate in severe childhood alopecia areata","volume":"165","author":"Royer","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib26","doi-asserted-by":"crossref","first-page":"71S","DOI":"10.1111\/1523-1747.ep12471884","article-title":"Topical immunotherapy in alopecia areata","volume":"96","author":"Happle","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib27","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1517\/14656566.2015.1084501","article-title":"Treatments options for alopecia","volume":"16","author":"Iorizzo","year":"2015","journal-title":"Exp Opin Pharmacother"},{"key":"10.1016\/j.jaad.2017.04.1142_bib28","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0190-9622(98)70048-9","article-title":"Efficacy of topical sensitizers in the treatment of alopecia areata","volume":"39","author":"Rokhsar","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib29","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1365-2133.1991.tb06064.x","article-title":"Alopecia areata in children: response to treatment with diphencyprone","volume":"125","author":"Hull","year":"1991","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0190-9622(96)90323-0","article-title":"Long-term results of topical immunotherapy in children with alopecia totalis or alopecia universalis","volume":"35","author":"Tosti","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaad.2009.10.031","article-title":"Alopecia areata update: part II. Treatment","volume":"62","author":"Alkhalifah","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib32","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/0190-9622(93)70238-O","article-title":"Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation","volume":"29","author":"Shapiro","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1468-3083.2011.04114.x","article-title":"Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata\u2013a large retrospective study on 142 patients with a self-controlled design","volume":"26","author":"Ohlmeier","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib34","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/ced.12776","article-title":"Retrospective review of diphencyprone in the treatment of alopecia areata","volume":"41","author":"Lamb","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib35","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jaad.2015.01.008","article-title":"Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series","volume":"72","author":"Durdu","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib36","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.clindermatol.2014.12.001","article-title":"Treatment of alopecia areata with squaric acid dibutylester","volume":"33","author":"Hill","year":"2015","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib37","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jaad.2015.04.064","article-title":"Squaric acid sensitization is not required for response in the treatment of alopecia areata","volume":"73","author":"Vedak","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/09546630410023601","article-title":"Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial","volume":"16","author":"Dall'Oglio","year":"2005","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jaad.2017.04.1142_bib39","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2015.06.045","article-title":"Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate","volume":"73","author":"Levy","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjd.12266","article-title":"A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis","volume":"169","author":"Ports","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib41","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/bjd.12517","article-title":"Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment","volume":"169","author":"Strober","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib42","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2017.04.1142_bib43","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib44","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2017.04.1142_bib45","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1038\/jid.2014.260","article-title":"Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis","volume":"134","author":"Craiglow","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib46","doi-asserted-by":"crossref","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaad.2017.04.1142_bib47","first-page":"e89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Crispin","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaad.2017.04.1142_bib48","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2016.09.006","article-title":"Tofacitinib for the treatment of alopecia areata and variants in adolescents","volume":"76","author":"Craiglow","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib50","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","article-title":"Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib","volume":"2","author":"Jabbari","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jaad.2017.04.1142_bib51","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.23871","article-title":"Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia","volume":"90","author":"Pieri","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib52","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jaci.2014.12.1867","article-title":"Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation","volume":"135","author":"Higgins","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib53","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/jdv.13598","article-title":"Efficacy of tofacitinib in treatment of alopecia universalis in two patients","volume":"30","author":"Gupta","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib54","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaad.2017.04.1142_bib55","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.jaad.2017.04.1142_bib56","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamadermatol.2015.4445","article-title":"Topical ruxolitinib for the treatment of alopecia universalis","volume":"152","author":"Craiglow","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib57","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nrd1901","article-title":"Anti-inflammatory effects of statins: clinical evidence and basic mechanisms","volume":"4","author":"Jain","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaad.2017.04.1142_bib58","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jaad.2014.11.006","article-title":"Treatment of alopecia areata with simvastatin\/ezetimibe","volume":"72","author":"Lattouf","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.04.1142_bib59","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jdermsci.2014.11.009","article-title":"The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in\u00a0vivo","volume":"77","author":"Keren","year":"2015","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2017.04.1142_bib60","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of\u00a0crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J Am Acad Dermatol"}],"updated-by":[{"DOI":"10.1016\/j.jaad.2024.08.009","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000}}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217318741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217318741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T15:57:03Z","timestamp":1723651023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962217318741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0190962217318741"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2017.04.1142","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alopecia areata","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.04.1142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(17)32702-0","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}